Lipodystrophy is a group of rare disorders in which the body partially or completely loses its fat tissue, triggering a cascade of metabolic problems that can look nothing like what you’d expect from “not having enough fat.” Without functional fat stores, the body has nowhere to safely store energy, so lipids end up deposited in organs like the liver and pancreas, often producing severe insulin resistance, diabetes, and dangerously high triglyceride levels. The condition comes in inherited and acquired forms, ranges from barely noticeable to life-altering, and is frequently misdiagnosed as something else entirely.
How Lipodystrophy Is Classified
The traditional way of sorting lipodystrophy relies on two questions: Did you inherit it, or did it develop later? And did you lose fat everywhere, or only in certain places? That gives four broad buckets: congenital generalized, congenital partial, acquired generalized, and acquired partial.1Endocrine Practice. Clinical Classification and Treatment of Congenital and Acquired Lipodystrophy In generalized forms, fat is missing from nearly the entire body. In partial forms, fat disappears from specific regions while accumulating in others, creating an uneven body shape that can be the first visible clue.
Congenital generalized lipodystrophy (CGL), sometimes called Berardinelli-Seip syndrome, is the most dramatic version. Babies are born with almost no subcutaneous fat, giving them a very muscular appearance. Four genetic subtypes have been identified, each linked to a different gene: CGL type 1 involves mutations in the AGPAT2 gene, type 2 involves BSCL2, type 3 involves CAV1, and type 4 involves PTRF.2PubMed Central. Congenital generalized lipodystrophies–new insights into metabolic dysfunction All are inherited in a recessive pattern, meaning both parents carry a copy of the faulty gene without being affected themselves. Studies of families with CGL have found a range of specific mutations in BSCL2 and AGPAT2, sometimes in the same mutation across multiple unrelated families, sometimes as unique compound mutations.3PubMed. Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome
Familial partial lipodystrophy (FPLD) is more subtle. People with FPLD typically have normal fat distribution in childhood but gradually lose fat from the arms, legs, and buttocks around puberty, while fat may accumulate in the face, neck, and trunk. One well-studied form, FPLD type 3, results from mutations in the PPARG gene, which encodes a receptor critical for fat cell development. When that receptor doesn’t work properly, the metabolic consequences can be severe.4PubMed Central. Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features
Acquired Forms and What Triggers Them
Not all lipodystrophy is written into your DNA. Acquired forms develop in people who were born with normal fat tissue and lost it later because of immune dysfunction, medications, or other triggers. Barraquer-Simons syndrome is an acquired partial form in which fat gradually vanishes from the face and upper body, often starting in childhood. Research points to complement system dysregulation as a central driver: patients tend to have low levels of the complement protein C3 and carry autoantibodies that target complement system proteins, suggesting the immune system is essentially attacking the fat tissue.5PubMed Central. Immunological features of patients affected by Barraquer-Simons syndrome
The most widely recognized acquired form, though, is linked to HIV treatment. Older antiretroviral drugs, particularly protease inhibitors and the nucleoside analog stavudine, are well documented to cause fat redistribution. In a European study of HIV-infected children, use of protease inhibitors and stavudine were independent predictors of fat redistribution, and the severity worsened the longer someone stayed on treatment.6PubMed. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe The classic pattern involves loss of fat from the face, arms, legs, and buttocks, paired with abnormal fat gain in the belly, breasts, and the back of the neck (the so-called “buffalo hump”). Newer antiretroviral regimens carry a much lower risk, but the legacy of older drug classes means many long-term HIV survivors still live with this form of lipodystrophy.
Why Losing Fat Causes So Many Problems
At first glance, losing body fat might not sound dangerous. But adipose tissue is not just insulation; it’s an endocrine organ. Fat cells produce leptin, a hormone that helps regulate appetite, blood sugar, and reproductive function. They also serve as a safe reservoir for circulating lipids. When that reservoir shrinks or disappears, lipids have nowhere to go and end up deposited in organs that aren’t designed to handle them. The liver is the most common casualty. Animal models of generalized lipodystrophy develop fatty liver disease, diabetes, and high blood lipids within weeks of birth, illustrating how quickly the metabolic dominoes fall when adipose tissue can’t do its job.7PubMed Central. Lipodystrophy Due to Adipose Tissue–Specific Insulin Receptor Knockout Results in Progressive NAFLD
In people with partial lipodystrophy, the liver fat burden can be strikingly high. A trial cohort of patients with partial lipodystrophy found average liver fat content above 11%, well into the range associated with non-alcoholic fatty liver disease. Roughly four out of five patients in that cohort already had liver fibrosis, and the liver fat level tracked closely with blood sugar and triglyceride levels.8PubMed Central. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort Severe high triglycerides can also lead to acute pancreatitis. In one study of familial partial lipodystrophy type 2, about 5% of patients had triglyceride levels extreme enough to trigger pancreatitis, and every one of those patients also had diabetes.9Journal of Clinical Lipidology. Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2 Patients without diabetes in that study had only mild triglyceride elevations and no pancreatitis, underscoring how much the metabolic complications cluster together.
Beyond Metabolism
The same trial cohort mentioned above revealed something that doesn’t always make it into textbook descriptions: the non-metabolic burden of partial lipodystrophy is enormous. Chronic pain affected about 78% of patients, over half had hypertension, and mood disorders were present in more than half as well.10PubMed Central. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort These aren’t footnotes. For many people living with lipodystrophy, daily pain and depression are as disabling as the metabolic complications.
The psychosocial toll compounds the physical problems. In HIV-associated lipodystrophy, quality-of-life research consistently finds that the visible body changes erode mental health. When patients themselves rate the severity of their fat changes, those ratings strongly correlate with worse quality-of-life scores across mental and physical domains. When doctors rate the same patients, the correlation with quality of life is much weaker, suggesting that clinicians underestimate how much the appearance changes affect well-being.11PubMed Central. Severity of lipodystrophy is associated with decreased health-related quality of life Body image distress tools have been specifically validated for this population, reflecting how central the cosmetic component is to the lived experience.12PubMed. Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire
Getting the Diagnosis Right
Lipodystrophy is underdiagnosed, in part because partial forms can look a lot like other conditions. A multicenter study comparing partial lipodystrophy patients with Cushing’s syndrome patients found striking overlap: facial fullness, a rounded “moon” face, dorsocervical fat pads, and excess hair growth were all more common in partial lipodystrophy, while muscle wasting and osteoporosis pointed toward Cushing’s. Partial lipodystrophy patients sometimes scored just as high on clinical Cushing’s scoring systems as patients who actually had Cushing’s, making lab tests essential for telling the two apart. Diabetes and very high triglycerides, meanwhile, were strongly associated with lipodystrophy rather than Cushing’s.13PubMed. Partial Lipodystrophy Mimicking Cushing’s Syndrome: Clinical and Metabolic Insights from a Multicenter Study Case reports have similarly noted that conditions like acromegaly can enter the differential before lipodystrophy is considered, particularly when fat redistribution creates a predominantly central pattern.14PubMed Central. A Visual Diagnosis: Lipodystrophy
Simple physical measurements can help. Skinfold thickness at the calf, measured with standard calipers, has shown promising accuracy as a screening tool. A cutoff of less than 8 mm at the calf identified lipodystrophy patients with sensitivity above 93% and specificity near 90% in one cross-sectional study.15PubMed Central. Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study For women with suspected familial partial lipodystrophy, triceps skinfold thickness below 20 mm and a leg fat percentage below about 30% may also point toward the diagnosis.16PubMed Central. Anthropometric measurements as a key diagnostic tool for familial partial lipodystrophy in women These aren’t definitive on their own, but they give primary care clinicians a cheap, fast reason to pursue genetic testing or specialist referral rather than writing off unusual fat distribution as garden-variety obesity.
Metreleptin and Other Treatments
Because leptin deficiency is central to the metabolic storm, replacing leptin has been the most transformative therapy to date. Metreleptin, a synthetic form of human leptin, is approved in several countries specifically for lipodystrophy. In pediatric patients treated for at least a year, average blood sugar (measured by A1c) dropped from about 8.3% to 6.5%, and median triglycerides fell roughly in half. Liver enzymes improved substantially, and paired liver biopsies showed reduced disease activity scores after several years of treatment.17PubMed Central. Effects of Metreleptin in Pediatric Patients With Lipodystrophy In adults, a three-year treatment period produced sustained reductions in A1c (averaging about a two-percentage-point drop) and triglycerides (down roughly a third), along with meaningful improvements in liver enzymes, particularly in patients who started with the most elevated values.18PubMed Central. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy
Metreleptin doesn’t restore fat tissue. It replaces the missing hormone signal, which in turn reins in appetite, improves insulin sensitivity, and lowers circulating lipids. It’s a daily injection, and access varies by country. In the United States, prescribing is restricted through a risk evaluation program because of theoretical concerns about antibody development and a hypothetical lymphoma risk. For many patients, though, it represents the single most effective tool available.
Beyond metreleptin, standard diabetes and lipid-lowering drugs remain part of the regimen. The multi-society practice guideline for lipodystrophy emphasizes diet as essential for managing metabolic complications, though the dietary challenge is unusual: patients are typically advised to follow a very low-fat diet (sometimes as low as 15–20% of calories from fat) because their bodies can’t safely store dietary lipids.19PubMed Central. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline Pioglitazone, a drug that activates the same PPAR-gamma receptor implicated in some genetic forms, has shown promise in individual cases, including one patient with Berardinelli-Seip syndrome whose blood sugar normalized for over five years on the drug.20Endocrinology, Diabetes and Metabolism Case Reports. Successful long-term use of pioglitazone in Berardinelli–Seip lipodystrophy-associated diabetes Case reports also suggest pioglitazone may help in atypical lipodystrophy forms where no clear genetic cause has been found.21PubMed. Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome
Surgical Approaches for Body Contour
Because lipodystrophy often creates a visually distressing mismatch between different body regions, surgical intervention is sometimes pursued to improve appearance and comfort rather than to address the underlying metabolism. In acquired partial lipodystrophy, where fat may accumulate heavily in the legs while the upper body wastes, large-volume liposuction has been reported. One case involved removal of nearly 19 liters of aspirate from the calves and thighs.22Australasian Journal of Plastic Surgery. Large-volume liposuction in acquired partial lipodystrophy: a case report In HIV-associated lipodystrophy, plastic surgeons have used a combination of ultrasonic and suction-assisted liposuction on the neck and trunk, along with procedures like facelifts and fat injections, to address the characteristic “buffalo hump” and facial wasting.23Annals of Plastic Surgery. Surgical Management of HIV-Associated Lipodystrophy These procedures treat the cosmetic symptoms, not the metabolic disease, and fat can re-accumulate if the underlying cause persists.
Reproductive Health and Pregnancy
The hormonal disruption from lipodystrophy, specifically the profound leptin deficiency, creates a particular set of challenges for reproductive health. Women with congenital generalized lipodystrophy often have excess androgens, irregular or absent ovulation, and difficulty conceiving.24PubMed Central. Pregnancy in a woman with congenital generalized lipodystrophy: leptin’s vital role in reproduction The connection between leptin and fertility is direct: the reproductive system relies on adequate leptin signaling as a gauge of the body’s energy status. When leptin is extremely low, the brain essentially concludes that conditions aren’t suitable for pregnancy and dials down reproductive function. Metreleptin therapy can restore ovulation in some of these patients, but pregnancy in generalized lipodystrophy still requires close metabolic monitoring because of the underlying insulin resistance and liver involvement.
Children with Lipodystrophy
In congenital forms, the metabolic complications can begin remarkably early. Children with CGL may present with accelerated growth in early childhood, driven by extreme insulin levels that act as a growth stimulus. One case of CGL type 2 documented a young girl with height well above the 97th percentile for age whose growth normalized after her insulin levels were brought under control with metreleptin and metformin.25PubMed Central. The clinical approach to child and adolescent patients with lipodystrophy: a series of international case discussions Advanced liver disease can also develop in childhood, making early diagnosis and intervention especially important. Because many pediatricians will see at most one case in a career, the muscular infant or the child with abnormally accelerated growth and fatty liver should trigger at least a brief consideration of lipodystrophy.
Gene Therapy on the Horizon
The genetic forms of lipodystrophy are, at least in theory, ideal candidates for gene therapy. If a single missing gene causes the disease, delivering a working copy of that gene could be curative. Preclinical work in mice lacking the BSCL2 gene (which causes CGL type 2) has shown real promise. In one study, a single injection of an adeno-associated virus vector carrying human BSCL2 restored visceral fat development, improved blood sugar, lowered triglycerides, and enhanced insulin sensitivity in lipodystrophic mice.26PubMed Central. Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy A refinement of this approach used tissue-selective viral vectors to target fat cells specifically, using a promoter active in adipose tissue and a microRNA sequence that silences any accidental expression in the liver. The adipose-targeted approach restored fat tissue and metabolic health without detectable liver expression, which matters because untargeted gene therapies can cause liver toxicity.27Gene Ther. Preclinical evaluation of tissue-selective gene therapies for congenital generalised lipodystrophy
These results are from mice, not people, and the jump to human trials involves significant hurdles around dosing, immune response, and long-term safety. But the fact that a one-time injection could rebuild fat tissue and normalize metabolism in an animal model represents a fundamentally different kind of treatment from lifetime daily injections of metreleptin. For a condition that currently has no cure, the early results are worth watching closely.